Table of Content

"1    INTRODUCTION    38
1.1    OBJECTIVES OF THE STUDY    38
1.2    MARKET DEFINITION    39
1.2.1    INCLUSIONS & EXCLUSIONS    39
TABLE 1    VACCINES MARKET: INCLUSIONS & EXCLUSIONS    39
1.3    MARKET SCOPE    40
1.3.1    MARKETS COVERED    40
FIGURE 1    VACCINES MARKET SEGMENTATION    40
1.3.2    YEARS CONSIDERED FOR THE STUDY    41
1.4    CURRENCY    41
1.5    LIMITATIONS    41
1.6    STAKEHOLDERS    42
1.7    SUMMARY OF CHANGES    42
2    RESEARCH METHODOLOGY    44
2.1    RESEARCH DATA    44
FIGURE 2    RESEARCH DESIGN    44
2.1.1    SECONDARY DATA    45
2.1.2    PRIMARY DATA    46
FIGURE 3    BREAKDOWN OF PRIMARIES: VACCINES MARKET    46
2.2    MARKET ESTIMATION METHODOLOGY    47
FIGURE 4    MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2020    47
2.2.1    INSIGHTS FROM PRIMARY EXPERTS    49
FIGURE 5    MARKET SIZE VALIDATION FROM PRIMARY SOURCES    49
2.3    MARKET GROWTH RATE PROJECTIONS    50
FIGURE 6    CAGR PROJECTIONS (SUPPLY-SIDE): VACCINES MARKET (EXCLUDING
COVID-19 VACCINES)    50
FIGURE 7    VACCINES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS    51
2.4    DATA TRIANGULATION    52
FIGURE 8    DATA TRIANGULATION METHODOLOGY    52
2.5    RESEARCH ASSUMPTIONS    53
2.6    RISK ANALYSIS    53
3    EXECUTIVE SUMMARY    54
FIGURE 9    VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)    54
FIGURE 10    COVID-19 VACCINES MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION)    55
FIGURE 11    VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2021 VS. 2026 (USD MILLION)    55
FIGURE 12    VACCINES MARKET, BY DISEASE INDICATION, 2021 VS. 2026 (USD MILLION)    56
FIGURE 13    VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2021 VS. 2026 (USD MILLION)    57
FIGURE 14    VACCINES MARKET SHARE (EXCLUDING COVID-19 VACCINES), BY END USER, 2021 VS. 2026    57
FIGURE 15    GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET (EXCLUDING
COVID-19 VACCINES)    58
4    PREMIUM INSIGHTS    60
4.1    VACCINES MARKET OVERVIEW (EXCLUDING COVID-19 VACCINES)    60
FIGURE 16    GROWING PREVALENCE OF EMERGING AND RE-EMERGING INFECTIOUS DISEASES TO DRIVE MARKET GROWTH    60
4.2    NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY AND COUNTRY (2020)    61
FIGURE 17    CONJUGATE VACCINES ACCOUNTED FOR THE LARGEST SHARE OF
THE NORTH AMERICAN VACCINES MARKET IN 2020    61
4.3    VACCINES MARKET (EXCLUDING COVID-19 VACCINES): GEOGRAPHIC GROWTH OPPORTUNITIES    62
FIGURE 18    ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE VACCINES MARKET FROM 2021 TO 2026    62
5    MARKET OVERVIEW    63
5.1    INTRODUCTION    63
5.2    MARKET DYNAMICS    63
FIGURE 19    VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    63
5.2.1    DRIVERS    64
5.2.1.1    Growing prevalence of emerging and re-emerging infectious diseases    64
TABLE 2    GLOBAL INCIDENCE OF INFECTIOUS DISEASES    65
5.2.1.2    Increasing focus on immunization programs    65
5.2.1.3    Growing government support for vaccine development    66
TABLE 3    NIH FUNDING FOR VACCINE RESEARCH, 2018–2022 (USD MILLION)    67
5.2.1.4    Increasing industry initiatives to enhance vaccine R&D    67
5.2.2    RESTRAINTS    67
5.2.2.1    High cost of vaccine development    67
5.2.2.2    Low purchasing power in developing countries    68
5.2.3    OPPORTUNITIES    68
5.2.3.1    High growth prospects in emerging markets    68
5.2.3.2    Focus on therapeutic vaccines    68
5.2.3.3    Use of adjuvants in vaccines    69
5.2.4    CHALLENGES    69
5.2.4.1    Inequitable access to vaccines    69
TABLE 4    IMMUNIZATION COVERAGE, BY DISEASE, 2020    70
5.2.4.2    Vaccine misinformation    70
5.3    IMPACT OF COVID-19 ON THE VACCINES MARKET    70
TABLE 5    APPROVED COVID-19 VACCINES (NOVEMBER 2021)    71
TABLE 6    COVID-19 VACCINES PIPELINE    72
FIGURE 20    VACCINES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019–2021 (USD BILLION)    73
5.4    RANGES/SCENARIO    74
FIGURE 21    SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE VACCINES MARKET    74
5.5    TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS    75
FIGURE 22    REVENUE SHIFT & NEW REVENUE POCKETS FOR VACCINE PROVIDERS    75
5.6    PATENT ANALYSIS    76
FIGURE 23    PATENTS GRANTED FOR VACCINES IN THE LAST 10 YEARS    76
TABLE 7    INDICATIVE LIST OF PATENTS IN THE VACCINES MARKET    76
5.7    PRICING ANALYSIS    77
TABLE 8    MEDIAN PRICE PER DOSE OF SOME VACCINES (2020) (USD)    77
5.8    VALUE CHAIN ANALYSIS    78
FIGURE 24    VALUE CHAIN ANALYSIS OF THE VACCINES MARKET: R&D AND CLINICAL TRIAL PHASE CONTRIBUTES MAXIMUM VALUE    78
5.9    ECOSYSTEM ANALYSIS    79
FIGURE 25    ECOSYSTEM ANALYSIS: VACCINES MARKET    79
5.10    REGULATORY LANDSCAPE    79
FIGURE 26    REGULATORY APPROVAL PROCESS FOR VACCINES    79
5.10.1    NORTH AMERICA    80
5.10.2    EUROPE    80
TABLE 9    REGULATORY AUTHORITIES IN EUROPE    80
5.10.3    ASIA PACIFIC    81
TABLE 10    REGULATORY AUTHORITIES IN ASIA PACIFIC    81
5.10.4    REST OF THE WORLD    81
5.11    PORTER’S FIVE FORCES ANALYSIS    82
TABLE 11    VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS    82
5.11.1    THREAT OF NEW ENTRANTS    82
5.11.2    THREAT OF SUBSTITUTES    82
5.11.3    BARGAINING POWER OF BUYERS    83
5.11.4    BARGAINING POWER OF SUPPLIERS    83
5.11.5    INTENSITY OF COMPETITIVE RIVALRY    83
5.12    KEY PIPELINE PRODUCTS    83
TABLE 12    KEY PIPELINE VACCINES: GLAXOSMITHKLINE PLC (UK)    83
TABLE 13    KEY PIPELINE VACCINES: PFIZER, INC. (US)    84
TABLE 14    KEY PIPELINE VACCINES: MERCK & CO., INC. (US)    85
TABLE 15    KEY PIPELINE VACCINES: SANOFI S.A. (FRANCE)    85
5.13    NEW VACCINE OPPORTUNITIES    86
5.13.1    HIV    86
5.13.1.1    HIV vaccines pipeline    86
5.13.1.2    HIV vaccines: Public-private initiatives and funding    88
5.13.2    MALARIA    89
5.13.2.1    Malaria vaccines pipeline    89
5.13.2.2    Malaria vaccines: Public-private initiatives and funding    90
5.13.3    ZIKA    90
5.13.3.1    Zika vaccines pipeline    90
5.13.3.2    Zika vaccines: Public-private initiatives and funding    91
5.13.4    EBOLA    91
5.13.4.1    Ebola vaccines pipeline    91
5.13.4.2    Ebola vaccines: Public-private initiatives and funding    92
5.13.4.3    Ebola projects funded by EC (2014–2020)    92
6    VACCINES MARKET, BY TECHNOLOGY    93
6.1    INTRODUCTION    94
TABLE 16    VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)    94
TABLE 17    COVID-19 VACCINES MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)    95
6.2    CONJUGATE VACCINES    95
6.2.1    CONJUGATE VACCINES HOLD THE LARGEST SHARE OF THE MARKET    95
TABLE 18    COST OF PEDIATRIC MENINGOCOCCAL CONJUGATE VACCINES AVAILABLE IN THE US    96
TABLE 19    COST OF ADULT MENINGOCOCCAL CONJUGATE VACCINES AVAILABLE IN
THE US    97
TABLE 20    CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION)    97
TABLE 21    NORTH AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    97
TABLE 22    EUROPE: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    98
TABLE 23    ASIA PACIFIC: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    98
TABLE 24    LATIN AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    98
6.3    RECOMBINANT VACCINES    99
6.3.1    LACK OF POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES ARE DRIVING R&D ON RECOMBINANT VACCINES    99
TABLE 25    EXAMPLES OF RECOMBINANT VACCINES    99
TABLE 26    RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION)    100
TABLE 27    NORTH AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    100
TABLE 28    EUROPE: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    100
TABLE 29    ASIA PACIFIC: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    101
TABLE 30    LATIN AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    101
6.4    INACTIVATED & SUBUNIT VACCINES    101
6.4.1    EASE OF STORAGE AND TRANSPORTATION HAVE MADE INACTIVATED & SUBUNIT VACCINES POPULAR    101
TABLE 31    EXAMPLES OF INACTIVATED & SUBUNIT VACCINES    102
TABLE 32    INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)    103
TABLE 33    NORTH AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    103
TABLE 34    EUROPE: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING
COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    103
TABLE 35    ASIA PACIFIC: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    104
TABLE 36    LATIN AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    104
6.5    LIVE ATTENUATED VACCINES    104
6.5.1    ISSUES IN PRESERVING AND MAINTAINING LIVE ATTENUATED VACCINES HAVE SLOWED MARKET GROWTH    104
TABLE 37    EXAMPLES OF LIVE ATTENUATED VACCINES    105
TABLE 38    LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION)    105
TABLE 39    NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING
COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    106
TABLE 40    EUROPE: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    106
TABLE 41    ASIA PACIFIC: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    106
TABLE 42    LATIN AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING
COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    107
6.6    TOXOID VACCINES    107
6.6.1    COMPANY INITIATIVES AND THE INTRODUCTION OF NEW VACCINES WILL SUPPORT MARKET GROWTH    107
TABLE 43    EXAMPLES OF TOXOID VACCINES    108
TABLE 44    TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)    108
TABLE 45    NORTH AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    109
TABLE 46    EUROPE: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)    109
TABLE 47    ASIA PACIFIC: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    109
TABLE 48    LATIN AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    110
6.7    VIRAL VECTOR VACCINES    110
6.7.1    VIRAL VECTOR VACCINES USE THE BODY’S OWN CELLS TO PRODUCE ANTIGENS    110
TABLE 49    EXAMPLES OF RECENTLY LAUNCHED VIRAL VECTOR VACCINES    110
TABLE 50    VIRAL VECTOR VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION)    111
7    VACCINES MARKET, BY TYPE    112
7.1    INTRODUCTION    113
TABLE 51    VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TYPE,
2019–2026 (USD MILLION)    113
TABLE 52    VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2019–2026 (USD MILLION)    113
7.2    MONOVALENT VACCINES    114
7.2.1    MONOVALENT VACCINES DOMINATE THE VACCINES MARKET    114
TABLE 53    EXAMPLES OF MONOVALENT VACCINES    114
TABLE 54    MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION)    115
TABLE 55    NORTH AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)    115
TABLE 56    EUROPE: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    115
TABLE 57    ASIA PACIFIC: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    116
TABLE 58    LATIN AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)    116
7.3    MULTIVALENT VACCINES    116
7.3.1    INCREASING INITIATIVES BY COMPANIES TO DEVELOP NEW MULTIVALENT VACCINES TO DRIVE MARKET GROWTH    116
TABLE 59    EXAMPLES OF MULTIVALENT VACCINES    117
TABLE 60    MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION)    118
TABLE 61    NORTH AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)    118
TABLE 62    EUROPE: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    118
TABLE 63    ASIA PACIFIC: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    119
TABLE 64    LATIN AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)    119
8    VACCINES MARKET, BY DISEASE INDICATION    120
8.1    INTRODUCTION    121
TABLE 65    VACCINES MARKET, BY DISEASE INDICATION, 2019–2026 (USD MILLION)    121
8.2    PNEUMOCOCCAL DISEASE    122
8.2.1    PNEUMOCOCCAL DISEASE IS THE LARGEST DISEASE INDICATION SEGMENT OF THE MARKET    122
TABLE 66    LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN
THE MARKET    122
TABLE 67    PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION,
2019–2026 (USD MILLION)    123
TABLE 68    NORTH AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)    123
TABLE 69    PNEUMOCOCCAL DISEASE VACCINES MARKET, BY BUYER,
2019–2026 (MILLION DOSES)    123
8.3    INFLUENZA    124
8.3.1    RISING DEMAND FOR INFLUENZA VACCINES FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET GROWTH    124
TABLE 70    LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET    125
TABLE 71    INFLUENZA VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)    125
TABLE 72    NORTH AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    126
8.4    COMBINATION VACCINES    126
8.4.1    INCREASING DEMAND FOR ALL-IN-ONE VACCINES IS DRIVING THE GROWTH OF THIS SEGMENT    126
TABLE 73    LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES IN
THE MARKET    127
TABLE 74    COMBINATION VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)    128
TABLE 75    NORTH AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    128
8.5    HPV    128
8.5.1    HPV VACCINES MARKET TO GROW AT THE HIGHEST RATE DURING
THE FORECAST PERIOD    128
TABLE 76    LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET    129
TABLE 77    HPV VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)    130
TABLE 78    NORTH AMERICA: HPV VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    130
TABLE 79    HPV VACCINES MARKET, BY BUYER, 2019–2026 (MILLION DOSES)    130
8.6    MENINGOCOCCAL DISEASE    131
8.6.1    RISING INCIDENCE OF MENINGOCOCCAL DISEASE TO SUPPORT
THE GROWTH OF THIS SEGMENT    131
TABLE 80    LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES IN THE MARKET    131
TABLE 81    MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION,
2019–2026 (USD MILLION)    132
TABLE 82    NORTH AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)    132
8.7    HERPES ZOSTER    132
8.7.1    HERPES ZOSTER VACCINES TO WITNESS STABLE DEMAND DURING
THE FORECAST PERIOD    132
TABLE 83    HERPES ZOSTER VACCINES MARKET, BY REGION,
2019–2026 (USD MILLION)    133
TABLE 84    NORTH AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    133
8.8    ROTAVIRUS    133
8.8.1    RISING INCIDENCE OF ROTAVIRUS INFECTIONS TO DRIVE MARKET GROWTH    133
TABLE 85    LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET    134
TABLE 86    ROTAVIRUS VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)    134
TABLE 87    NORTH AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    134
TABLE 88    ROTAVIRUS VACCINES MARKET, BY BUYER, 2019–2026 (MILLION DOSES)    135
8.9    MMR    135
8.9.1    RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA IS SUPPORTING THE GROWTH OF THIS SEGMENT    135
TABLE 89    LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET    135
TABLE 90    MMR VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)    136
TABLE 91    NORTH AMERICA: MMR VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    136
8.10    VARICELLA    136
8.10.1    PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE THE DEMAND FOR VARICELLA VACCINES    136
TABLE 92    LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET    137
TABLE 93    VARICELLA VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)    137
TABLE 94    NORTH AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    137
8.11    HEPATITIS    138
8.11.1    HIGH PREVALENCE OF HEPATITIS INFECTIONS TO DRIVE THE DEMAND FOR IMMUNIZATION    138
TABLE 95    LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET    138
TABLE 96    HEPATITIS VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)    139
TABLE 97    NORTH AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    139
8.12    DTP    139
8.12.1    INCREASING ACCESSIBILITY OF DTP VACCINES IN DEVELOPING COUNTRIES TO DRIVE MARKET GROWTH    139
TABLE 98    LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET    140
TABLE 99    DTP VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)    140
TABLE 100    NORTH AMERICA: DTP VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    140
8.13    POLIO    141
8.13.1    GOVERNMENT INITIATIVES TO SUPPORT THE GROWTH OF THIS SEGMENT    141
TABLE 101    POLIO VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)    142
TABLE 102    NORTH AMERICA: POLIO VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    142
8.14    COVID-19    142
8.14.1    EMERGENCE OF SARS-COV-2 VARIANTS COULD MAKE BOOSTER DOSES NECESSARY    142
TABLE 103    LIST OF WHO PREQUALIFIED COVID-19 VACCINES    143
TABLE 104    COVID-19 VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)    143
TABLE 105    NORTH AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    144
TABLE 106    COVID-19 VACCINE DELIVERIES, BY COUNTRY (MILLION DOSES)    144
8.15    OTHER DISEASE INDICATIONS    145
TABLE 107    LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS    145
TABLE 108    VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION,
2019–2026 (USD MILLION)    146
TABLE 109    NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2019–2026 (USD MILLION)    146
9    VACCINES MARKET, BY ROUTE OF ADMINISTRATION    147
9.1    INTRODUCTION    148
TABLE 110    VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    148
TABLE 111    VACCINES MARKET (INCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    148
9.2    INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION    149
9.2.1    INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION ACCOUNTED FOR THE LARGEST MARKET SHARE    149
TABLE 112    ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION    149
TABLE 113    VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION,
2019–2026 (USD MILLION)    150
TABLE 114    NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)    150
TABLE 115    EUROPE: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)    151
TABLE 116    ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)    151
TABLE 117    LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)    152
9.3    ORAL ADMINISTRATION    152
9.3.1    POSSIBILITY OF IRRITATION OF THE GASTRIC MUCOSA IS LIMITING
THE GROWTH OF THIS SEGMENT    152
TABLE 118    VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)    153
TABLE 119    NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    153
TABLE 120    EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    153
TABLE 121    ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    154
TABLE 122    LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)    154
9.4    OTHER ROUTES OF ADMINISTRATION    154
TABLE 123    VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)    155
TABLE 124    NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)    155
TABLE 125    EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)    156
TABLE 126    ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    156
TABLE 127    LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)    156
10    VACCINES MARKET, BY END USER    157
10.1    INTRODUCTION    158
TABLE 128    VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER,
2019–2026 (USD MILLION)    158
10.2    PEDIATRIC VACCINES    158
10.2.1    PEDIATRIC VACCINES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET    158
TABLE 129    PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION)    159
TABLE 130    NORTH AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    159
TABLE 131    EUROPE: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    160
TABLE 132    ASIA PACIFIC: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    160
TABLE 133    LATIN AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    160
10.3    ADULT VACCINES    161
10.3.1    ADULT VACCINES SEGMENT TO GROW AT THE HIGHEST CAGR DURING
THE FORECAST PERIOD    161
TABLE 134    ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)    162
TABLE 135    NORTH AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    162
TABLE 136    EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)    162
TABLE 137    ASIA PACIFIC: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    163
TABLE 138    LATIN AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)    163
11    VACCINES MARKET, BY REGION    164
11.1    INTRODUCTION    165
FIGURE 27    VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES (EXCLUDING COVID-19 VACCINES)    165
TABLE 139    VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)    166
TABLE 140    VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION,
2019–2026 (USD MILLION)    166
11.2    NORTH AMERICA    167
FIGURE 28    NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)    168
TABLE 141    NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)    169
TABLE 142    NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION)    169
TABLE 143    NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    170
TABLE 144    NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2019–2026 (USD MILLION)    170
TABLE 145    NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    170
TABLE 146    NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)    171
11.2.1    US    171
11.2.1.1    The US is the largest market for vaccines globally    171
TABLE 147    US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION)    172
TABLE 148    US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)    172
TABLE 149    US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2019–2026 (USD MILLION)    173
TABLE 150    US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    173
TABLE 151    US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)    173
11.2.2    CANADA    174
11.2.2.1    High incidence of infectious diseases is driving the demand for vaccines in the country    174
TABLE 152    CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION)    174
TABLE 153    CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    175
TABLE 154    CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)    175
TABLE 155    CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    175
TABLE 156    CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)    176

11.3    EUROPE    176
TABLE 157    EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)    177
TABLE 158    EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION)    177
TABLE 159    EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    178
TABLE 160    EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)    178
TABLE 161    EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    178
TABLE 162    EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)    179
11.3.1    GERMANY    179
11.3.1.1    Significant investments in R&D to support market growth    179
TABLE 163    GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    180
TABLE 164    GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)    180
TABLE 165    GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    180
TABLE 166    GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)    181
11.3.2    UK    181
11.3.2.1    Launch of new products and collaborations to support market growth in the UK in the coming years    181
TABLE 167    UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)    182
TABLE 168    UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2019–2026 (USD MILLION)    182
TABLE 169    UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    182
TABLE 170    UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)    183
11.3.3    FRANCE    183
11.3.3.1    Favorable government initiatives for immunization to support market growth in France    183
TABLE 171    FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    184
TABLE 172    FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)    184
TABLE 173    FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    184
TABLE 174    FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)    185
11.3.4    ITALY    185
11.3.4.1    Italy is the third-largest donor for the International Finance Facility for Immunization    185
TABLE 175    ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    185
TABLE 176    ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)    186
TABLE 177    ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    186
TABLE 178    ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)    186
11.3.5    SPAIN    187
11.3.5.1    Increasing investments in vaccine development by private organizations to support market growth in Spain    187
TABLE 179    SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    187
TABLE 180    SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)    187
TABLE 181    SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    188
TABLE 182    SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)    188
11.3.6    REST OF EUROPE    188
TABLE 183    ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    189
TABLE 184    ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2019–2026 (USD MILLION)    189
TABLE 185    ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    190
TABLE 186    ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)    190"
"11.4    ASIA PACIFIC    191
TABLE 187    ASIA PACIFIC: HEALTHCARE EXPENDITURE PER CAPITA, BY COUNTRY,
2017 VS. 2018 VS. 2019 (USD)    191
FIGURE 29    ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)    192
TABLE 188    ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)    193
TABLE 189    ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION)    193
TABLE 190    ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    194
TABLE 191    ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2019–2026 (USD MILLION)    194
TABLE 192    ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    194
TABLE 193    ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)    195
11.4.1    CHINA    195
11.4.1.1    Growing investments in the biotechnology sector to drive market growth in China    195
TABLE 194    CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    196
TABLE 195    CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)    196
TABLE 196    CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    196
TABLE 197    CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)    197
11.4.2    JAPAN    197
11.4.2.1    Government initiatives for increasing the accessibility of vaccines to drive market growth in Japan    197
TABLE 198    JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    197
TABLE 199    JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)    198
TABLE 200    JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    198
TABLE 201    JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)    198
11.4.3    INDIA    199
11.4.3.1    Growth of the biotechnology sector and development of new vaccines to support market growth in India    199
TABLE 202    INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    199
TABLE 203    INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)    200
TABLE 204    INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    200
TABLE 205    INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)    200
11.4.4    SOUTH KOREA    201
11.4.4.1    Strong government boost to develop vaccine hubs in the country is expected to drive market growth    201
TABLE 206    SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    201
TABLE 207    SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2019–2026 (USD MILLION)    201
TABLE 208    SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    202
TABLE 209    SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)    202
11.4.5    REST OF ASIA PACIFIC    202
TABLE 210    ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    203
TABLE 211    ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)    203
TABLE 212    ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    203
TABLE 213    ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)    204
11.5    LATIN AMERICA    204
TABLE 214    LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)    204
TABLE 215    LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION)    205
TABLE 216    LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    205
TABLE 217    LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2019–2026 (USD MILLION)    206
TABLE 218    LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    206
TABLE 219    LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)    206
11.5.1    BRAZIL    207
11.5.1.1    Rising focus on vaccination from governmental and non-governmental organizations to drive market growth    207
TABLE 220    BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    207
TABLE 221    BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)    207
TABLE 222    BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    208
TABLE 223    BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)    208
11.5.2    REST OF LATIN AMERICA    208
TABLE 224    ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)    209
TABLE 225    ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)    209
TABLE 226    ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    209
TABLE 227    ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)    210
11.6    MIDDLE EAST AND AFRICA    210
11.6.1    HIGH DEMAND FOR VACCINES DUE TO THE PREVALENCE OF INFECTIOUS DISEASES WILL DRIVE MARKET GROWTH    210
TABLE 228    MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)    211
TABLE 229    MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)    211
TABLE 230    MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)    212
TABLE 231    MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)    212
TABLE 232    MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)    212
12    COMPETITIVE LANDSCAPE    213
12.1    OVERVIEW    213
12.2    KEY PLAYER STRATEGIES/RIGHT TO WIN    214
FIGURE 30    KEY PLAYER STRATEGIES IN THE VACCINES MARKET, 2018-2021    214
12.3    MARKET SHARE ANALYSIS    215
FIGURE 31    VACCINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020    215
12.4    REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS    216
FIGURE 32    REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE VACCINES MARKET, 2016–2020    216
12.5    COMPANY EVALUATION QUADRANT    217
12.5.1    STARS    217
12.5.2    EMERGING LEADERS    217
12.5.3    PERVASIVE PLAYERS    217
12.5.4    PARTICIPANTS    217
FIGURE 33    VACCINES MARKET: COMPANY EVALUATION QUADRANT, 2020    218
12.6    COMPANY EVALUATION QUADRANT: START-UPS/SMES    219
12.6.1    PROGRESSIVE COMPANIES    219
12.6.2    STARTING BLOCKS    219
12.6.3    RESPONSIVE COMPANIES    219
12.6.4    DYNAMIC COMPANIES    219
FIGURE 34    VACCINES MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020    220
12.7    DISEASE INDICATION FOOTPRINT OF COMPANIES    221
TABLE 233    DISEASE INDICATION PORTFOLIO ANALYSIS: VACCINES MARKET (2020)    221
12.8    REGIONAL FOOTPRINT OF COMPANIES    222
TABLE 234    REGIONAL FOOTPRINT ANALYSIS: VACCINES MARKET (2020)    222
12.9    COMPETITIVE SCENARIO    223
12.9.1    PRODUCT LAUNCHERS & APPROVALS    223
TABLE 235    VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2018–NOVEMBER 2021    223
12.9.2    DEALS    225
TABLE 236    VACCINES MARKET: DEALS, JANUARY 2018–NOVEMBER 2021    225
12.9.3    OTHER DEVELOPMENTS    228
TABLE 237    VACCINES MARKET: OTHER DEVELOPMENTS,
JANUARY 2018–NOVEMBER 2021    228
13    COMPANY PROFILES    229
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1    KEY COMPANIES    229
13.1.1    GLAXOSMITHKLINE PLC    229
TABLE 238    GLAXOSMITHKLINE PLC: BUSINESS OVERVIEW    229
FIGURE 35    GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2020)    230
13.1.2    MERCK & CO., INC.    237
TABLE 239    MERCK & CO., INC.: BUSINESS OVERVIEW    237
FIGURE 36    MERCK & CO., INC.: COMPANY SNAPSHOT (2020)    238
13.1.3    PFIZER, INC.    242
TABLE 240    PFIZER, INC.: BUSINESS OVERVIEW    242
FIGURE 37    PFIZER, INC.: COMPANY SNAPSHOT (2020)    243
13.1.4    SANOFI SA    248
TABLE 241    SANOFI SA: BUSINESS OVERVIEW    248
FIGURE 38    SANOFI SA: COMPANY SNAPSHOT (2020)    249
13.1.5    CSL LIMITED    254
TABLE 242    CSL LIMITED: BUSINESS OVERVIEW    254
FIGURE 39    CSL LIMITED: COMPANY SNAPSHOT (2020)    255
13.1.6    EMERGENT BIOSOLUTIONS, INC.    258
TABLE 243    EMERGENT BIOSOLUTIONS, INC.: BUSINESS OVERVIEW    258
FIGURE 40    MERGENT BIOSOLUTIONS, INC.: COMPANY SNAPSHOT (2020)    259
13.1.7    JOHNSON & JOHNSON    261
TABLE 244    JOHNSON & JOHNSON: BUSINESS OVERVIEW    261
FIGURE 41    JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020)    262
13.1.8    ASTRAZENECA PLC    264
TABLE 245    ASTRAZENECA PLC: BUSINESS OVERVIEW    264
FIGURE 42    ASTRAZENECA PLC: COMPANY SNAPSHOT (2020)    265
13.1.9    SERUM INSTITUTE OF INDIA PVT., LTD.    267
TABLE 246    SERUM INSTITUTE OF INDIA PVT. LTD.: BUSINESS OVERVIEW    267
13.1.10    BAVARIAN NORDIC A/S    271
TABLE 247    BAVARIAN NORDIC A/S: BUSINESS OVERVIEW    271
FIGURE 43    BAVARIAN NORDIC A/S: COMPANY SNAPSHOT (2020)    272
13.1.11    MITSUBISHI TANABE PHARMA CORPORATION    274
TABLE 248    MITSUBISHI TANABE PHARMA CORPORATION: BUSINESS OVERVIEW    274
13.1.12    DAIICHI SANKYO COMPANY, LIMITED    276
TABLE 249    DAIICHI SANKYO COMPANY, LIMITED: BUSINESS OVERVIEW    276
FIGURE 44    DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2020)    276
13.1.13    PANACEA BIOTEC    278
TABLE 250    PANACEA BIOTEC: BUSINESS OVERVIEW    278
FIGURE 45    PANACEA BIOTEC: COMPANY SNAPSHOT (2020)    279
13.1.14    BIOLOGICAL E LIMITED    281
TABLE 251    BIOLOGICAL E LIMITED: BUSINESS OVERVIEW    281
13.1.15    BHARAT BIOTECH    284
TABLE 252    BHARAT BIOTECH: BUSINESS OVERVIEW    284
13.1.16    NOVAVAX, INC.    286
TABLE 253    NOVAVAX, INC.: BUSINESS OVERVIEW    286
FIGURE 46    NOVAVAX, INC.: COMPANY SNAPSHOT (2020)    286
13.1.17    FSUE NPO MICROGEN    288
TABLE 254    FSUE NPO MICROGEN: BUSINESS OVERVIEW    288
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2    OTHER COMPANIES    289
13.2.1    SINOVAC BIOTECH LTD.    289
13.2.2    INCEPTA VACCINE LTD.    290
13.2.3    VALNEVA SE    290
13.2.4    VBI VACCINES INC.    291
13.2.5    PT BIO FARMA (PERSERO)    291
13.2.6    INOVIO PHARMACEUTICALS, INC.    292
13.2.7    CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.    292
13.2.8    INDIAN IMMUNOLOGICALS LIMITED    293
14    APPENDIX    294
14.1    DISCUSSION GUIDE    294
14.2    KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL    299
14.3    AVAILABLE CUSTOMIZATIONS    301
14.4    RELATED REPORTS    301
14.5    AUTHOR DETAILS    302"